USE OF COLLAGEN POLYVINYLPYRROLIDONE FOR INFLAMMATION OF LUNGS AND FIBROSIS IN PATIENTS INFECTED WITH SARS-CoV2 VIRUS (COVID-19) Russian patent published in 2025 - IPC A61K38/39 A61K31/79 A61P31/14 

FIELD: medicine.

SUBSTANCE: present invention relates to the use of polymerised collagen type I in patients with a positive result on Covid-19 and to an intramuscular dosing regimen every 12 hours for 3 days, and then every 24 hours for 4 days in patients with mild to moderate Covid-19 disease or to an intramuscular dosing regimen every 12 hours for 7 days in patients with severe or semi-critical disease caused by Covid-19. Besides, the clinical evolution of each patient is analysed individually (Fig. 13–17 and 20–21) and by groups (Fig. 18 and 19) taking into account the following parameters: SpO2 percentage, temperature, heart rate, breathing frequency, cough periods, chest pain, headache, dyspnea, odynophagia, anosmia, loss of taste sensation, presence of arthralgia and myalgia, clinical improvement was recorded in all cases.

EFFECT: disclosed is the use of collagen polyvinylpyrrolidone for pulmonary inflammation and fibrosis in patients infected with the SARS-CoV2 (Covid-19) virus.

8 cl, 21 dwg, 1 tbl